Author Topic: (AAN) Alemtuzumab's immunosuppressive effect doesn't last more than 48 months  (Read 151 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9821
  • MS diagnosed 1980
  • Location: Pacific Northwest
Presented at the annual AAN conference in Vancouver, BC, in April 2016:

Quote
S2.008 - Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months
 
Luca Durelli,1Stefania De Mercanti,1Simona Rolla,2Angele Cucci,1Valentina Bardina,2Eleonora Cocco,3Anton Vladic,4Silva Soldo-Butkovic,5Mario Habek,4Ivan Adamec,4Pietro Annovazzi,6Dana Horakova,7Franco Novelli,2Marinella Clerico8

1Orbassano, Italy, 2Torino, Italy, 3Cagliari, Italy, 4Zagreb, Croatia, 5Osijek, Croatia, 6Gallarate, Italy, 7Prague, Czech Republic, 8Orbassano (TO), Italy

Disclosures

 L. Durelli: None. S. De Mercanti: None. S. Rolla: None. A. Cucci: None. V. Bardina: None. E. Cocco: None. A. Vladic: None. S. Soldo-Butkovic: None. M. Habek: None. I. Adamec: None. P. Annovazzi: ; Dr Annovazzi received personal compensation for consulting, speaking and serving on a scientific advisory board from Biogen Idec, Novartis and Teva pharmaceuticals. D. Horakova: ; Support for research activities from Biogen Idec. F. Novelli: None. M. Clerico: None.

OBJECTIVE:

Phenotypic and functional analysis of CD4+ T cell subsets and of immunologically relevant molecules mRNA serum levels after alemtuzumab in relapsing remitting multiple sclerosis(RRMS) patients: A four-year follow-up.

BACKGROUND:

Alemtuzumab induces a long-standing lymphopenia, particularly of T CD4+ subset, and it is highly effective in RRMS

DESIGN/METHODS:

 Multicenter follow-up of 29 alemtuzumab-treated RRMS patients from 6 European sites in the CARE-MS I and CARE-MS II trials. Patients received two courses of alemtuzumab at month 0 and 12. Clinical and immunological evaluation were performed at months 0, 6, 12, 18, 24, 36 and 48. The percentages of Treg, Th1 and Th17 cells in the peripheral blood mononuclear cells(PBMC) were evaluated by FACS analysis. mRNA levels of cytokines, chemokines, chemokine receptors and transcriptional factors with pro-inflammatory (IL-1β, IL-2, IL-6, IL-12, IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-26, IFN-γ, Tbet, RORC, TNF-α, CCR3, CCR4, CCR5, CCR6, CXCR3, CXCL10, CCL20, VLA4) or anti-inflammatory function (IL-10, IL-27, TGF-β and FoxP3) were quantified by TaqManŽ low density array(TLDA) real-time polymerase chain reaction in whole blood. Treg suppressor activity on Myelin basic protein(MBP)-specific Th17 and Th1 cells was assessed by IL-17 and IFN-γ ELISPOT on total PBMC and PBMC depleted of CD25highT cells.

RESULTS:

No patient received further alemtuzumab courses after the first two years. CD4+ lymphocyte percentage decreased and slowly returned to basal levels only at Month 48. Within this population, no significant variation was observed in Th1 and Th17 cells, with the exception of an increase of Th17 cells in patients with a documented relapse. Treg cells percentage and suppressive function significantly increased at Month 24 and returned to baseline levels within Month 48.

CONCLUSIONS:

The long-term follow-up of immune system reconstitution showed that alemtuzumab effects lasted not more that 48 months. Clinical and MRI follow-up could suggest the need for repeated alemtuzumab courses.
« Last Edit: April 28, 2016, 10:03:25 am by agate »
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

 

Related Topics

  Subject / Started by Replies Last post
1 Replies
129 Views
Last post October 12, 2018, 08:34:59 am
by agate
5 Replies
73 Views
Last post February 19, 2024, 09:07:28 pm
by agate
0 Replies
25 Views
Last post February 15, 2022, 03:10:12 pm
by agate
0 Replies
12 Views
Last post April 21, 2023, 09:43:11 pm
by agate
0 Replies
12 Views
Last post August 17, 2023, 09:27:54 pm
by agate